Last mentioned: 15h ago
Across the most recent 8 stories covering Johnson & Johnson — 13% positive, 25% negative, 63% neutral sentiment, averaging 6/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Quarterly Earnings
Expected announcement of financial results and pipeline updates for PTGX and OEZVY.
BofA Price Target Hike
Bank of America increases price target, highlighting R&D productivity and MedTech growth.
Fast-Track Approval
USFDA grants approval for Tecvayli-Darzalex combination via fast-track voucher program.
12-Month High
JNJ shares reach a new yearly peak following FDA approval for multiple myeloma combo.
TGA Approval
Australian regulatory body approves the Virtual Nodule Clinic for clinical use.
Pipeline Update
Initial Phase 1 data released for LB2102 in solid tumors at a major medical conference.
JNJ-2113 Phase 3 Progress
Johnson & Johnson advances oral peptide JNJ-2113 into pivotal trials.
Manufacturing Expansion
Obelisc facility in Belgium reaches full operational status for clinical and commercial supply.
FY 2025 Earnings
Legend Biotech reports full-year results and commercial highlights.
Takeda Partnership
Protagonist signs a global licensing agreement for rusfertide with $300M upfront.
Series A Funding
Company raises $14M to scale its AI clinical platform globally.
FDA Clearance
Optellum receives first-of-its-kind FDA clearance for AI lung cancer decision support.
The settlement removes a major litigation distraction, allowing Johnson & Johnson to redirect resources toward its core pharmaceutical and medtech segments, which generate $85B in annual revenue.
Source: 1190talkradio.iheart.com · manilatimes.net
The 2nd Circuit ruling revives mass tort litigation linking prenatal acetaminophen to autism, exposing Kenvue and retailers to billions in potential liability. The decision hinges on admissibility of novel scientific evidence, challenging Daubert standards and regulatory orthodoxy.
Source: fox5atlanta.com · fox32chicago.com
Protagonist Therapeutics (PTGX) is set to report quarterly earnings this Wednesday, with investors focused on the commercial trajectory of its Takeda-partnered rusfertide. The results come at a critical juncture as the company transitions from a clinical-stage R&D house to a commercially-oriented biotech entity.
Bank of America has raised its price target for Johnson & Johnson, citing a robust outlook for the company's Innovative Medicine and MedTech divisions. The upgrade reflects growing confidence in JNJ's oncology pipeline and its ability to navigate upcoming patent expirations for key assets.
Legend Biotech (LEGN) has announced its fourth-quarter and full-year 2025 financial results, showcasing a significant surge in net trade sales for its CAR-T therapy, Carvykti. The company continues to expand its manufacturing footprint and advance its pipeline in solid tumors, solidifying its position as a leader in the cell therapy market.
Optellum has received regulatory clearance from Australia’s Therapeutic Goods Administration (TGA) for its AI-driven lung nodule management platform. The approval enables the deployment of the Virtual Nodule Clinic to help Australian clinicians identify and treat early-stage lung cancer more effectively.
Protagonist Therapeutics has seen its share price skyrocket by 120% following significant clinical and regulatory milestones, yet a major institutional investor has disclosed a $170 million exit. This divergence highlights a classic 'sell the news' moment or strategic rebalancing amidst a period of high valuation for the peptide-based drug developer.
Source: fool.com · finance.yahoo.com
Genmab reported full-year 2025 revenue of $3.72B, missing analyst estimates by $50M, while initiating a robust 2026 outlook focused on proprietary oncology assets. Despite a dip in full-year profit, the company is accelerating its transition from a royalty-dependent model to a self-sustaining commercial powerhouse.
Source: insidermonkey.com · seekingalpha.com
This page surfaces every story mentioning Johnson & Johnson across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Johnson & Johnson was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |